Equities
IndustrialsGeneral Industrials
  • Price (USD)58.30
  • Today's Change-0.91 / -1.54%
  • Shares traded2.39m
  • 1 Year change-17.91%
  • Beta1.1351
Data delayed at least 15 minutes, as of Sep 30 2022 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Fortive Corporation is a provider of essential technologies for connected workflow solutions across a range of end-markets. It operates through three segments: Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. Intelligent Operating Solutions segment offers various Products and services under a range of brands, including Accruent, Fluke, Gordian, Industrial Scientific, Intelex, Pruftechnik, and Servicechannel. Precision Technologies segment provides electrical test and measurement instruments and services, energetic material devices, and a range of sensor and control system solutions. Advanced Healthcare Solutions segment provides hardware, consumables, software and services that helps in the customers' workflows, including instrument sterilization and device reprocessing, instrument tracking, cell therapy equipment design and manufacturing, biomedical test tools, radiation safety monitoring, end-to-end clinical productivity solutions and asset

  • Revenue in USD (TTM)5.52bn
  • Net income in USD658.60m
  • Incorporated2015
  • Employees18.00k
  • Location
    Fortive Corp6920 Seaway BlvdEVERETT 98203-5829United StatesUSA
  • Phone+1 (425) 446-5000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.fortive.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
FTV:NYQ since
announced
Transaction
value
ProVation Medical IncDeal completed03 Dec 202103 Dec 2021Deal completed-21.48%1.43bn
Data delayed at least 15 minutes, as of Sep 30 2022 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MKS Instruments, Inc.3.01bn555.60m5.47bn6.00k8.261.478.211.829.979.9754.0456.180.67272.696.57502,133.3012.4011.3013.7512.5845.6445.9318.4415.913.6329.710.206612.1426.5917.8957.5039.3835.304.81
Bruker Corporation2.48bn273.90m7.25bn7.77k27.127.4819.882.931.801.8016.336.540.76511.646.69318,840.908.537.6811.8310.5050.7447.9411.149.571.6225.470.544712.9621.668.4675.6012.5319.920.00
Cognex Corporation1.09bn258.67m7.31bn2.26k29.005.2626.266.731.451.456.118.020.54743.796.69481,146.7013.0415.1714.4916.4071.2974.2723.8228.483.32--0.0044.8727.8814.3958.8614.223.8210.68
Bio Rad Laboratories Inc2.87bn-1.94bn12.33bn7.90k--1.38--4.30-66.32-66.3295.80300.450.20661.966.76363,415.10-13.9724.42-14.6126.3657.0555.45-67.6683.244.220.16680.11830.0014.817.1611.55177.08-3.10--
Avantor Inc7.60bn572.10m13.80bn13.50k23.273.0914.081.820.88030.880311.796.630.61615.675.99563,170.405.09--5.79--34.2132.518.272.421.054.660.594--15.5260.60876.92--30.02--
PerkinElmer, Inc.5.02bn674.23m15.22bn16.70k22.222.1213.523.035.435.4240.5756.780.43794.035.22300,600.005.886.636.497.7054.3152.3113.4314.321.428.020.38516.5533.9519.0929.5534.3225.800.00
Waters Corporation2.90bn702.12m16.39bn7.80k23.8541.8619.595.6511.4711.4747.416.540.94423.204.91371,868.3022.8516.2029.7719.4458.1158.4824.2124.161.5524.150.7910.0017.785.1532.845.8512.12--
Fortive Corp5.52bn658.60m21.06bn18.00k32.662.2319.233.821.811.8015.1826.560.36094.546.27306,422.204.315.235.196.4157.3955.0011.9415.080.72679.600.280414.0613.38-0.4635-58.09-4.77-14.6014.87
Mettler-Toledo International Inc.3.87bn820.63m25.16bn15.60k31.493,464.4826.986.5135.4935.49167.190.32271.193.966.30247,779.9025.3321.4337.1130.0758.3258.0021.2318.720.770122.370.99630.0020.518.1927.5814.88-2.79--
AMETEK, Inc.5.92bn1.09bn26.10bn18.50k24.173.7518.624.414.704.7025.4430.270.49854.616.50319,865.009.228.8410.8010.2034.6236.2018.4916.730.884917.510.264716.8822.177.6313.4814.0911.8317.32
Keysight Technologies Inc5.27bn1.11bn27.81bn14.70k25.807.1220.885.286.036.0328.6921.860.67342.366.76368,601.4014.147.6816.849.2564.0758.1721.0011.732.3818.390.31370.0017.0611.1142.5821.6913.84--
Illumina, Inc.4.69bn-20.00m28.93bn9.80k--2.7790.676.16-0.0815-0.081529.9866.520.3893.397.82478,775.50-0.165810.93-0.196412.9667.5468.81-0.426323.160.8237--0.14280.0039.7313.5416.1610.49-5.15--
Data as of Sep 30 2022. Currency figures normalised to Fortive Corp's reporting currency: US Dollar USD

Institutional shareholders

51.41%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Investment Management, Inc.as of 31 Jul 202241.29m11.61%
The Vanguard Group, Inc.as of 30 Jun 202237.90m10.66%
Wellington Management Co. LLPas of 30 Jun 202219.34m5.44%
BlackRock Fund Advisorsas of 30 Jun 202216.27m4.58%
RBC Global Asset Management (UK) Ltd.as of 30 Jun 202215.42m4.33%
SSgA Funds Management, Inc.as of 30 Jun 202213.47m3.79%
Flossbach von Storch AGas of 30 Jun 202213.10m3.68%
Viking Global Investors LPas of 30 Jun 202211.80m3.32%
Fidelity Management & Research Co. LLCas of 30 Jun 20227.36m2.07%
Geode Capital Management LLCas of 30 Jun 20226.93m1.95%
More ▼
Data from 30 Jun 2022 - 31 Aug 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.